FDA Drug Recalls

Recalls / Class II

Class IID-0173-2024

Product

CITALOPRAM Tablets, USP, 20MG, 100 Tablets, Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 0378-6232-01

Brand name
Citalopram
Generic name
Citalopram
Active ingredient
Citalopram Hydrobromide
Route
Oral
NDCs
0378-6231, 0378-6232, 0378-6233
FDA application
ANDA077042
Affected lot / code info
Batch 3131748

Why it was recalled

CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

Recalling firm

Firm
CARDINAL HEALTHCARE
Manufacturer
Mylan Pharmaceuticals Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
7200 Cardinal Pl W, Dublin, Ohio 43017-1094

Distribution

Quantity
1 unit
Distribution pattern
Nationwide USA

Timeline

Recall initiated
2022-01-26
FDA classified
2023-12-26
Posted by FDA
2024-01-03
Terminated
2024-09-29
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0173-2024. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Citalopram · FDA Drug Recalls